Loading
Adding pembrolizumab to trastuzumab and chemotherapy improved response and progression-free survival in HER2-positive advanced gastric cancer, with the benefit concentrated in tumours that also express PD-L1.
Phase 3 placebo-controlled trial of 698 patients with untreated HER2-positive advanced gastric or junctional adenocarcinoma randomised to pembrolizumab or placebo with trastuzumab and fluoropyrimidine-platinum chemotherapy.
Median progression-free survival was 10.0 versus 8.1 months (hazard ratio 0.72) overall and 10.8 versus 7.2 months in PD-L1 combined positive score 1 or more (hazard ratio 0.70); response was 73 versus 60 percent, and the final analysis showed an overall survival benefit in the PD-L1-positive population (20.0 versus 15.7 months).
Pembrolizumab with trastuzumab and chemotherapy is the first-line standard for HER2-positive gastric cancer with a PD-L1 combined positive score of 1 or more.
Shares KEYNOTE-811, Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab.
Shares The Lancet, Pembrolizumab.